Increased ERCC1 protein expression is associated with suboptimal debulking in advanced epithelial ovarian cancer

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2447-2452

  Lin, Feili ^a   Lin, Kaiqing ^a   Xie, Xing ^a   Zhou, Caiyun ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Advanced epithelial ovarian cancer; Biological feature; ERCC1; Suboptimal debulking

Indexed keywords

CA 125 ANTIGEN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; ASCITES; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; CA-125 ANTIGEN; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 77955072111     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
4. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR and Marks JR: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11: 3686-3696, 2005.
5. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR and Marks JR: Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190: 910-925, 2004.
6. Aletti GD, Gostout BS and Podratz KC: Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100: 33-37, 2006.
7. Eltabbach GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K and Morgan A: Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 95: 377-383, 2004. (Pubitemid 39445875)
8. Chi DS, Venkatraman ES, Masson V and Hoskins WJ: The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77: 227-231, 2000.
9. Wood RD: DNA repair in eukaryotes. Annu Rev Biochem 65: 135-167, 1996.
10. Sharova NP: How does a cell repair damaged DNA? Biochemistry (Mosc) 70: 275-291, 2005.
11. Altaha R, Liang X, Yu JJ and Reed E: Excision repair cross complementing group 1: gene expression and platinum resistance. Int J Mol Med 14: 959-970, 2004.
12. Lin K, Ye D and Xie X: Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 18: 1007-1012, 2008.
13. Scartozzi M, De Nictolis M, Galizia E, Carassai P, Bianchi F, Berardi R, Gesuita R, Piga A, Cellerino R and Porfiri E: Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. Eur J Cancer 39: 1144-1149, 2003.
14. Zheng J, Benedict WF, Xu HJ, Hu SX, Kim TM, Velicescu M, Wan M, Cofer KF and Dubeau L: Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst 87: 1146-1153, 1995.
15. Jiang J, Wu RF and Wang ZH: Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 77: 995-1000, 2002.
16. Onda T, Yoshikawa H, Yasugi T, Yamada M, Matsumoto K and Taketani Y: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92: 1026-1043, 2005.
17. Soegaard Andersen E, Knudsen A, Svarrer T, Lund B, Nielsen K, Grove A and Tetsche M: The results of treatment of epithelial ovarian cancer after centralization of primary surgery. Results from North Jutland, Denmark. Gynecol Oncol 99: 552-556, 2005.
18. Hacker NF: Cytoreduction for advanced ovarian cancer in perspective. Gynecol Cancer 6: 15-160, 1996.
19. Selvakumaran M, Pisarcik DA and Bao R: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63: 1311-1316, 2003. (Pubitemid 36348710)
20. Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM and Mes-Masson AM: Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9: 820-289, 2007.
21. Shen-Gunther J and Mannel RS: Ascites as a predictor of ovarian malignancy. Gynecol Oncol 87: 77-83, 2002.
22. Aletti GD, Dowdy SC and Podratz KC: Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol 105: 84-89, 2007.
23. Sood AK, Sorosky JI and Dolan M: Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res 5: 2485-2490, 1999.
24. Eisenkop SM, Friedman RL and Wang HJ: Complete cytoreductive surgery is feasible and maximises survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69: 103-108, 1998.
25. Makar AP, Baekelandt M and Trope CG: The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56: 175-180, 1995.
26. Singleton TP, Perrone T and Oakley G: Activation of c-erbB-2 and prognosis in ovarian carcinoma. Cancer 73: 1460-1466, 1994.
27. Fader AN and Rose PG: Role of surgery in ovarian carcinoma. J Clin Oncol 25: 2873-2883, 2007.
28. Piver MS, Lele SB and Marchetti DL: Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol 6: 1679-1684, 1988.